Metformin is the most widely prescribed and best-studied medication for insulin resistance, and it remains the standard first-line treatment for most people. But “best” depends on your specific situation: whether you have prediabetes, type 2 diabetes, PCOS, or significant weight to lose. Several other medications also improve insulin sensitivity through different mechanisms, and some people benefit from combinations or alternatives.
Why Metformin Is the Standard First Choice
Metformin works primarily by reducing the amount of glucose your liver produces. Your liver constantly releases stored sugar into your bloodstream, and in insulin resistance, this process goes into overdrive. Metformin dials it back by shifting how your liver cells manage energy: it activates a cellular energy sensor called AMPK, which tells cells to stop producing glucose and start burning fuel instead. This lowers both fasting blood sugar and the overall demand on your insulin-producing cells.
The evidence behind metformin is unusually strong. The Diabetes Prevention Program, one of the largest and longest trials of its kind, followed participants with prediabetes for over two decades. After 22 years, those who took metformin had an 18% lower risk of developing type 2 diabetes compared to placebo, and the onset of diabetes was delayed by about two years. Lifestyle changes (diet and exercise) performed even better at 25% risk reduction, but metformin offered a reliable pharmaceutical floor for people who couldn’t sustain those changes.
Metformin is also inexpensive, available as a generic, and has a long safety track record. The most common downside is gastrointestinal trouble: diarrhea, nausea, and stomach pain affect a meaningful number of users, and roughly 10% of people can’t tolerate it at all. If that happens, switching to the extended-release version often solves the problem. Both forms typically start at 500 mg daily and can be increased gradually up to 2,000 mg. The slow titration is specifically designed to let your gut adjust. Metformin is safe for most people, but it’s not appropriate if your kidney function (measured by eGFR) falls below 30, and starting it isn’t recommended once eGFR drops below 45.
GLP-1 and Dual-Action Medications
Newer injectable medications originally developed for type 2 diabetes have become major players in treating insulin resistance, partly because they also drive substantial weight loss. Semaglutide and tirzepatide both improve insulin sensitivity, but they do so through different pathways, and the difference matters.
Tirzepatide activates two gut hormone receptors (GLP-1 and GIP) rather than just one, and head-to-head comparisons show it produces greater improvement in insulin sensitivity than semaglutide. Notably, this advantage isn’t simply because people lose more weight on tirzepatide. When researchers measured insulin sensitivity using gold-standard clamp testing, tirzepatide delivered more improvement per unit of weight lost, suggesting it has direct effects on how the body processes insulin beyond what weight loss alone would explain. With semaglutide, the link between weight loss and insulin sensitivity improvement was weaker and less consistent.
These medications are prescribed as weekly injections and require a gradual dose increase over several months. They tend to cause nausea, especially early on, though this usually fades. The practical barrier for many people is cost: without insurance coverage, they can run over $1,000 per month. They’re most often prescribed when insulin resistance coexists with obesity or type 2 diabetes, where the combined benefits of blood sugar control and weight reduction justify the expense.
Pioglitazone: A Direct Insulin Sensitizer
Pioglitazone belongs to a class called thiazolidinediones, and it works differently from metformin. While metformin focuses on the liver, pioglitazone improves how your muscle and fat cells respond to insulin. It essentially makes these tissues better at pulling glucose out of the bloodstream when insulin signals them to do so.
Pioglitazone is genuinely effective at reducing insulin resistance, and it’s sometimes added when metformin alone isn’t enough. The trade-off is a specific set of side effects that limits its use: it can cause fluid retention, weight gain (typically from increased fat storage under the skin rather than around organs), and a small increase in fracture risk, particularly in women. Because of these concerns, it’s used more selectively than metformin and is rarely a first choice.
SGLT2 Inhibitors: An Indirect Approach
SGLT2 inhibitors take a completely different approach. Instead of changing how your cells respond to insulin, they block your kidneys from reabsorbing glucose, so you excrete excess sugar in your urine. This reduces blood sugar levels by 30% to 60% of what the kidneys would normally reabsorb, typically lowering A1c by 0.5% to 1.0%. The glucose loss also promotes modest weight reduction and lowers blood pressure.
These medications don’t directly fix insulin resistance, but by reducing the glucose load your body has to manage, they ease the strain on your insulin-producing cells and create conditions where sensitivity can improve over time. They’ve also shown significant benefits for heart and kidney health, which makes them a strong option for people with insulin resistance who also have cardiovascular risk factors or early kidney disease.
Insulin Resistance in PCOS
Polycystic ovary syndrome involves a specific pattern of insulin resistance tied to hormonal imbalances, and the treatment landscape looks a bit different. Metformin has been the go-to for years, but a supplement called myo-inositol has gained traction as an alternative, particularly for women at a normal weight.
In clinical comparisons, myo-inositol (typically 2,000 mg twice daily with folic acid) and metformin (1,500 mg daily) produced similar improvements in insulin levels during glucose tolerance testing and comparable reductions in androgen hormones like testosterone. Both restored menstrual regularity in over 90% of patients. The key difference was tolerability: in one study, six out of the metformin group dropped out due to gastrointestinal side effects, while the myo-inositol group had better adherence and more pregnancies. For lean women with PCOS and insulin resistance, myo-inositol is increasingly considered a reasonable first option.
Berberine as a Natural Alternative
Berberine, a compound found in several plants, has shown blood-sugar-lowering effects comparable to metformin in small clinical trials. In one three-month study of 36 people with type 2 diabetes, berberine reduced A1c by 7.5%, fasting glucose by 6.9%, and post-meal glucose by 11.1%, numbers that closely matched metformin’s performance in the same trial.
The caveat is scale. Metformin’s benefits have been confirmed across massive studies spanning decades and thousands of participants. Berberine’s evidence comes from much smaller and shorter trials, mostly conducted in specific populations. It’s a reasonable option if you can’t tolerate metformin or prefer a supplement-based approach, but the confidence level behind it is lower. It can also interact with other medications, since it affects how the liver processes certain drugs.
How Doctors Choose Between Options
The “best” medication depends on what’s driving your insulin resistance and what other health issues are in play. In practice, the decision usually follows a pattern. Metformin comes first for most people because it’s effective, safe, affordable, and backed by the deepest evidence base. If weight is a major contributing factor, a GLP-1 or dual-action injectable may be added or used instead, since the weight loss amplifies the insulin-sensitizing effect. If there are heart or kidney concerns, an SGLT2 inhibitor often enters the picture. Pioglitazone fills a niche when other options haven’t brought insulin sensitivity under control.
For many people, the answer isn’t a single medication but a combination. Metformin handles liver glucose production, a GLP-1 medication reduces appetite and body weight, and lifestyle changes (even modest ones like 30 minutes of daily walking) improve how muscle cells respond to insulin. These approaches target different pieces of the same problem, and they tend to work better together than any one does alone.